

DAFTAR PUSTAKA

1. Prijatni I. Kesehatan Reproduksi dan Keluarga Berencana. modul bahan ajar cetak kebidana. 2016.
2. BKKBN. Keluarga Berencana Kontrasepsi. Jurnal Keperawatan. 2014.
3. Mulyani N. Keluarga Berencana dan Alat Kontrasepsi. In: Keluarga Berencana dan Alat Kontrasepsi. 2016.
4. Soleha S. Studi Tentang Dampak Program Keluarga Berencana Di Desa Bangun Mulya Kabupaten Penajam Paser Utara. Ilmu Pemerintah. 2016;
5. Katzman DK, Taddeo D, Baltzer F, Elliott A, Harvey J, Lipnowski S, et al. Emergency contraception. Vol. 15, Paediatrics and Child Health. 2010.
6. Wilkinson T. Access to Emergency Contraception After Removal of Age Restrictions. Pediatrics. 2017;140(1).
7. Shohel M, Rahman MM, Zaman A, Uddin MMN, Al-Amin MM, Reza HM. A systematic review of effectiveness and safety of different regimens of levonorgestrel oral tablets for emergency contraception. BMC Womens Health. 2014 Jan 4;14(1):54.
8. Akintomide H, James A, Moffat M, Barnes P, Rankin J. Original research: Systematic review of copper intrauterine contraception continuation in young nulliparous women based on intrauterine device type. BMJ Open. 2022 Oct;12(10).
9. Karena Z V, Shah H, Vaghela H, Chauhan K, Desai PK, Chitalwala AR. Clinical Utility of Mifepristone: Apprising the Expanding Horizons. Cureus. 2022 Aug;14(8).
10. Shen J, Che Y, Showell E, Chen K, Cheng L. Interventions for emergency contraception. Cochrane Database Syst Rev. 2019 Jan;2019(1).
11. Li HWR, Resche-Rigon M, Bagchi IC, Gemzell-Danielsson K, Glasier A. Does ulipristal acetate emergency contraception (ella®) interfere with implantation? Contraception. 2019 Nov 1;100(5):386–90.
12. Agency EM. Suspension of ulipristal acetate for uterine fibroids during ongoing EMA review of liver injury risk. 2020.

13. WHO. Emergency contraception. 2021.
14. Schreiber CA, Barnhart K. Contraception. In: Yen & Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management: Eighth Edition. 2019.
15. Glasier A, Gebbie A. Family Planning/Contraception. *Int Encycl Public Heal*. 2016 Oct 6;92–101.
16. Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. U.S. medical eligibility criteria for contraceptive use, 2016. *MMWR Recomm Reports*. 2016;65(3):1–104.
17. Kahlenborn C, Peck R, Severs WB. Mechanism of action of levonorgestrel emergency contraception. *Linacre Q*. 2015 Feb;82(1):18.
18. Kaymak O, Simşek Y, Doğanay M, Yıldız Y, Mollamahmutoğlu L. Ectopic pregnancy following levonorgestrel emergency contraception: a case report. *J Turkish Ger Gynecol Assoc*. 2010;11(3):168–9.
19. Black K. Emergency contraception: Oral and intrauterine options. *Aust Fam Physician*. 2017. p. 722–6.
20. Beatty MN, Blumenthal PD. The levonorgestrel-releasing intrauterine system: Safety, efficacy, and patient acceptability. *Ther Clin Risk Manag*. 2009;5(1):561.
21. Kim SK, Shin SJ, Yoo Y, Kim NH, Kim DS, Zhang D, et al. Oral toxicity of isotretinoin, misoprostol, methotrexate, mifepristone and levonorgestrel as pregnancy category X medications in female mice. *Exp Ther Med*. 2015;9(3):853.
22. Kavanaugh ML, Jerman J. Contraceptive method use in the United States: trends and characteristics between 2008, 2012 and 2014. *Contraception*. 2018 Jan;97(1):14.
23. Peipert JF, Zhao Q, Allsworth JE, Petrosky E, Madden T, Eisenberg D, et al. Continuation and Satisfaction of Reversible Contraception. *Obstet Gynecol*. 2011 May;117(5):1105.
24. Goldstuck ND, Wildemeersch D. Practical Advice for Emergency IUD Contraception in Young Women. *Obstet Gynecol Int*. 2015;2015:1–6.

25. Strasser J, Borkowski L, Couillard M, Allina A, Wood SF. Access to Removal of Long-acting Reversible Contraceptive Methods Is an Essential Component of High-Quality Contraceptive Care. *Womens Health Issues*. 2017 May;27(3):253–5.
26. Suparman E. Kontrasepsi Darurat dan Permasalahannya. *Med Scope J*. 2021;3(1):94.
27. Grandi G, Farulla A, Sileo FG, Facchinetti F. Levonorgestrel-releasing intra-uterine systems as female contraceptives. *Expert Opin Pharmacother*. 2018 May;19(7):677–86.
28. Grimes DA, Lopez LM, Schulz KF, Stanwood NL. Immediate postabortal insertion of intrauterine devices. *Cochrane Database Syst Rev*. 2010 Jun;(6).
29. Farmer M, Webb A. Intrauterine device insertion-related complications: can they be predicted? *J Fam Plan Reprod Heal care*. 2003 Oct;29(4):227–31.
30. Cleland K, Raymond EG, Westley E, Trussell J. Emergency contraception review: evidence-based recommendations for clinicians. *Clin Obstet Gynecol*. 2014;57(4):741.
31. Barnett C, Moehner S, Do Minh T, Heinemann K. Perforation risk and intra-uterine devices: results of the EURAS-IUD 5-year extension study. *Eur J Contracept Reprod Health Care*. 2017 Nov;22(6):424–8.
32. Dzuba IG, Grossman D, Schreiber CA. Off-label indications for mifepristone in gynecology and obstetrics. *Contraception*. 2015 Sep;92(3):203–5.
33. Katta S, Lal A, Maradana JL, Velamala PR, Trivedi N. Hypokalemia associated with mifepristone use in the treatment of Cushing's syndrome. *Endocrinol Diabetes Metab Case Reports*. 2019 Jan;2019(1).
34. Kulier R, Kapp N, Gülmezoglu AM, Hofmeyr GJ, Cheng L, Campana A. Medical methods for first trimester abortion. Kulier R, editor. *Cochrane database Syst Rev*. 2004 Jan;(2).
35. Baev OR, Rumyantseva VP, Tsyachnyu O V., Kozlova OA, Sukhikh GT. Outcomes of mifepristone usage for cervical ripening and induction of labour in full-term pregnancy. Randomized controlled trial. *Eur J Obstet*

- Gynecol Reprod Biol. 2017 Oct;217:144–9.
36. Gemzell-Danielsson K, Berger C, Lalitkumar PGL. Emergency contraception -- mechanisms of action. *Contraception*. 2013 Mar;87(3):300–8.
 37. Kim A, Bridgeman MB. Ulipristal Acetate (ella): A Selective Progesterone Receptor Modulator For Emergency Contraception. *Pharm Ther*. 2011 Jun;36(6):325.
 38. Nallasamy S, Kim J, Sitruk-Ware R, Bagchi M, Bagchi I. Ulipristal Blocks Ovulation by Inhibiting Progesterone Receptor–Dependent Pathways Intrinsic to the Ovary. *Reprod Sci*. 2013 Apr;20(4):371.
 39. Brache V, Cochon L, Duijkers IJM, Levy DP, Kapp N, Monteil C, et al. A prospective, randomized, pharmacodynamic study of quick-starting a desogestrel progestin-only pill following ulipristal acetate for emergency contraception. *Hum Reprod*. 2015;30(12):2785–93.
 40. Yuan J, Zhao W, Yan M, Zhu Q, Qin G, Qiu J, et al. Ulipristal Acetate Antagonizes the Inhibitory Effect of Progesterone on Ciliary Beat Frequency and Upregulates Steroid Receptor Expression Levels in Human Fallopian Tubes. *Reprod Sci*. 2015 Dec;22(12):1516–23.
 41. Berger C, Boggavarapu NR, Menezes J, Lalitkumar PGL, Gemzell-Danielsson K. Effects of ulipristal acetate on human embryo attachment and endometrial cell gene expression in an in vitro co-culture system. *Hum Reprod*. 2015 Sep;30(4):800–11.
 42. Munuce MJ, Zumoffen C, Cicaré J, Caille A, Ghersevich S, Bahamondes L. Effect of exposure to ulipristal acetate on sperm function. *Eur J Contracept Reprod Health Care*. 2012 Dec;17(6):428–37.
 43. Hoseini FS, Eslami M, Abbasi M, Noroozi Fashkhami F, Besharati S. A randomized, controlled trial of levonorgestrel vs. the yuzpe regimen as emergency contraception method among Iranian women. *Iran J Public Health*. 2013;42(10):1158–66.
 44. Carbonell JL, Garcia R, Gonzalez A, Breto A, Sanchez C. Mifepristone 5 mg versus 10 mg for emergency contraception: Double-blind randomized

- clinical trial. *Int J Womens Health*. 2015;7:95–102.
45. Li HWR, Lo SST, Ng EHY, Ho PC. Efficacy of ulipristal acetate for emergency contraception and its effect on the subsequent bleeding pattern when administered before or after ovulation. *Hum Reprod*. 2016 Jun;31(6):1200–7.
 46. Turok DK, Gero A, Simmons RG, Kaiser JE, Stoddard GJ, Sexsmith CD, et al. Levonorgestrel vs. Copper Intrauterine Devices for Emergency Contraception. *N Engl J Med*. 2021;384(4):335–44.
 47. BakenRa A, Gero A, Sanders J, Simmons R, Fay K, Turok DK. Pregnancy Risk by Frequency and Timing of Unprotected Intercourse Before Intrauterine Device Placement for Emergency Contraception. *Obstet Gynecol*. 2021 Jul;138(1):79–84.
 48. Fay KE, Clement AC, Gero A, Kaiser JE, Sanders JN, BakenRa AA, et al. Rates of pregnancy among levonorgestrel and copper intrauterine emergency contraception initiators: Implications for backup contraception recommendations. *Contraception*. 2021 Nov 1;104(5):561–6.
 49. Thiyagarajan DK, Basit ; Hajira, Jeanmonod ; Rebecca. *Physiology, Menstrual Cycle*. Treasure Island: StatPearls Publishing; 2023.
 50. Koyama A, Hagopian L, Linden J. Emerging Options for Emergency Contraception. *Clin Med Insights Reprod Heal*. 2013 Jan;7(7):23.
 51. Westley E, Schwarz EB. Emergency contraception: global challenges, new opportunities. *Contraception*. 2012 May;85(5):429–31.
 52. Brache V, Cochon L, Jesam C, Maldonado R, Salvatierra AM, Levy DP, et al. Immediate pre-ovulatory administration of 30 mg ulipristal acetate significantly delays follicular rupture. *Hum Reprod*. 2010;25(9):2256–63.
 53. Stratton P, Levens ED, Hartog B, Piquion J, Wei Q, Merino M, et al. Endometrial effects of a single early-luteal dose of the selective progesterone receptor modulator CDB-2914. *Fertil Steril*. 2010 Apr;93(6):2035.
 54. Matyanga CMJ, Dzingirai B. Clinical Pharmacology of Hormonal Emergency Contraceptive Pills. *Int J Reprod Med*. 2018 Oct;2018:1–5.

55. Sivin I. Utility and drawbacks of continuous use of a copper T IUD for 20 years. *Contraception*. 2007 Jun;75(6 Suppl).

